Dual-AAV splits the gene in two and hopes both halves land in the same cell. Mini-STRC removes the disordered N-terminal so the gene fits one AAV. Both are workarounds for the same constraint: AAV can't carry more than 4.7 kb.
Programmable recombinases ignore that constraint. They insert full-length DNA at a specific genomic location, independent of the cell's own repair machinery. No splitting. No truncation. Full-length stereocilin, precisely integrated.
In January 2026, Eli Lilly signed a $1.12 billion deal with Seamless Therapeutics for exclusive rights to this technology in hearing loss. That's not a research grant. That's a bet.
Traditional CRISPR cuts DNA and relies on the cell to repair it. Recombinases are different: they catalyze the insertion directly, no double-strand break needed, no dependence on HDR or NHEJ pathways. The recombinase recognizes a specific target sequence, opens it, and threads the new DNA in. One enzyme, one reaction, one result.
| Property | Dual-AAV | Mini-STRC | Recombinase |
|---|---|---|---|
| Payload size | Full-length (split across 2 vectors) | Truncated (3.2-3.5 kb) | Full-length (single insertion) |
| Vectors needed | 2 AAV particles | 1 AAV particle | 1 vector (AAV or LNP) |
| Integration | Episomal (no integration) | Episomal (no integration) | Site-specific genomic integration |
| Persistence | Years (episomal loss possible) | Years (episomal loss possible) | Permanent (integrated into genome) |
| Efficiency bottleneck | Co-transduction + recombination (27%) | Single transduction (78%) | Integration efficiency (unknown) |
| Clinical status | Phase 1/2 (OTOF only) | Preclinical (computational) | Preclinical (no cochlear data) |
Eli Lilly spent $2.4 billion on hearing loss in 6 months. $1.12B for Seamless recombinases (Jan 2026) and $1.3B for Rznomics RNA editing (May 2025). That's not a side project. Big pharma sees cochlear gene therapy as a massive market. For context: ~2.3 million patients carry STRC mutations alone. DFNB16 is the second most common genetic hearing loss.
If recombinases work in cochlear hair cells, they solve every problem at once: full-length protein, single vector, permanent integration, no episomal loss. Our mini-STRC approach remains valid (smaller payload, proven AAV delivery), but it's a workaround. Recombinases would be the direct solution.
The catch: nobody has demonstrated recombinase-mediated gene insertion in inner ear hair cells. The technology works in cell lines and some in vivo contexts, but cochlear delivery and OHC-specific targeting are unsolved. Timeline: 3-5 years to preclinical data, optimistically.
Reality check: Programmable recombinases are not yet demonstrated in cochlear cells. Lilly's deal covers the technology platform, not a specific STRC program. Integration efficiency, off-target insertion rates, and OHC-specific delivery remain unknown. This is a 5-10 year horizon technology for STRC specifically.